Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). - Test2 - elhamkhani - TriplyDB

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

http://www.wikidata.org/entity/Q38375349

about

Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.Molecular insights into desmoid tumors.Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS).Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (ST Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis.Aberrant Regulation of Notch3 Signaling Pathway in Polycystic Kidney Disease.HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami

P2860

Q38659874-3A0A9194-D138-4639-A38F-FC5D3368838C Q47121056-12955814-2EF7-4ED3-8053-BBD10E6230D9 Q47188880-87E4578E-B73E-461D-A9E0-07A06F8E1995 Q47274504-309F1B30-1246-4172-9C9C-F04F2B3A504F Q47666781-BE4F6885-BAE0-46A0-B9C4-77A8557B9790 Q48243797-8E148167-80E3-4815-8ED5-16C05BFB3E3D Q49789913-6D3AF6AF-6FFB-475B-AB2C-57D1BEF63AB5 Q55004240-E775A626-0B4A-4FE5-97FD-E7248046A0CC

P2860

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

http://www.wikidata.org/entity/Q38375349

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Clinical Activity of the γ-Sec ...... ors (Aggressive Fibromatosis).

@en

type

label

Clinical Activity of the γ-Sec ...... ors (Aggressive Fibromatosis).

@en

prefLabel

Clinical Activity of the γ-Sec ...... ors (Aggressive Fibromatosis).

@en

P1433

Q38375349-A8AAD332-39E6-4CB8-9072-0733A27B58A9

P1476

Q38375349-4089F9BF-D2B7-483F-A3EA-747331A90A82

P2093

Q38375349-15B91D79-745E-4239-B56E-5F2376696BB1

Q38375349-25066E39-59DE-4A07-9F52-FD303FCB0A86

Q38375349-3B887B69-A271-415F-A27D-262ECD6A5CE4

Q38375349-451135A8-A0A9-459E-B315-C117450B2E7C

Q38375349-4A7CEB64-A228-485C-9ED7-A21A65EB9128

Q38375349-8C8CE493-E429-4A52-B0C5-B5B4B621A49A

Q38375349-A4597893-506C-4EB6-A640-E1D07C98E59C

Q38375349-B399746B-5660-4F5A-9B02-D84793A740ED

Q38375349-B513723D-DD17-4FD9-9CC2-34C9DF32890B

Q38375349-BF3F8CCA-0DFA-4E83-A90B-E87C1D6D4908

P2860

Q38375349-07583244-9C28-4B76-8F94-078EDE77F1B4

Q38375349-0C412832-47B6-42B2-B3F6-6DD72079D98D

Q38375349-0E445349-BEDE-47EF-84F0-A7DD84FADAC7

Q38375349-12B3DA36-8501-4919-8F1C-79A8A08919CA

Q38375349-1404930A-58CF-426D-8250-46596AD5F680

Q38375349-144E7CE2-07BB-4F81-BD0B-D734D1A38F42

Q38375349-1C7FFDBE-2CCA-4B0C-B4DC-0DC2D27BFD67

Q38375349-2567FCDD-A344-4D0B-9837-13AFB200E473

Q38375349-30DD3628-46AD-495A-A658-60A6C4FA90D2

Q38375349-32354EF4-D28B-41D8-8014-116A41558D0A

P304

Q38375349-38B68303-5BCC-47C4-8614-699F9F631BA1

P31

Q38375349-7551A8CC-7794-45C0-93F0-7C5239D6774F

P356

Q38375349-20AB9B93-4DBD-4F1F-8BE3-2122635D37C8

P407

Q38375349-F800B6CB-B51C-4938-8282-470FE779393D

P433

Q38375349-E9B80401-12B2-4E9F-A036-337881155C91

P478

Q38375349-0AD66199-2188-4BD3-BC1E-BFC1C48DC22C

P577

Q38375349-F00D4ADC-3191-4CD4-90BA-06A220109D1E

P698

Q38375349-7627C23E-FFAB-4262-8F4E-55DBD6DD8FC9

P932

Q38375349-D7B2B29B-9198-4CBF-A859-EC723898260D

P356

JCO.2016.71.1994

P1433

Journal of Clinical Oncology

P1476

Clinical Activity of the γ-Sec ...... ors (Aggressive Fibromatosis).

@en

P2093

Alice P Chen

http://www.w3.org/2001/XMLSchema#string

Amul Choudhary

http://www.w3.org/2001/XMLSchema#string

Ann Lih

http://www.w3.org/2001/XMLSchema#string

Baris Turkbey

http://www.w3.org/2001/XMLSchema#string

Eric Polley

http://www.w3.org/2001/XMLSchema#string

Geraldine O'Sullivan Coyne

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Khanh T Do

http://www.w3.org/2001/XMLSchema#string

Lamin Juwara

http://www.w3.org/2001/XMLSchema#string

Lee J Helman

http://www.w3.org/2001/XMLSchema#string

P2860

Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?

TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC

Activity of Sorafenib against desmoid tumor/deep fibromatosis

Update on desmoid tumors

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review

Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor

The canonical Notch signaling pathway: unfolding the activation mechanism.

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

P304

1561-1569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.71.1994

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28350521

http://www.w3.org/2001/XMLSchema#string

P932

5455706

http://www.w3.org/2001/XMLSchema#string